Navigation Links
Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
Date:9/26/2007

ntamicin Topical

CollaRx GENTAMICIN TOPICAL is a biodegradable collagen-based dressing that delivers the broad-spectrum antibiotic, gentamicin, directly to the infected wound environment for localized action. The product is already approved and marketed in countries outside the US as GENTAMICIN SURGICAL IMPLANT where a number of published clinical case studies and anecdotal reports from clinicians have pointed to its effectiveness in the treatment of infected chronic wounds of various etiologies. Innocoll plans to develop the topical indication for the global market. Initially the product will be investigated for the treatment of diabetic foot infections across the full range of severities in a series of phase 2 trials and has appointed the full-service Clinical Research Organization, Premier Research Group, to co-ordinate these studies. The lead indication is the treatment of diabetic ulcers having a mild infection where the safety and efficacy of CollaRx GENTAMICIN TOPICAL will be compared to an orally administered antibiotic. In subsequent phase 2 trials, Innocoll will investigate the product as an adjunct to systemic antibiotic therapy for treating diabetic foot infections of higher severity and also as a method to prevent diabetic ulcers from becoming clinically infected.

Currently, there are no topically applied antibiotics marketed in the US that are specifically indicated for the treatment of infected diabetic foot ulcers and recent market research independently performed by L.E.K. Consulting forecast peak annual revenues for CollaRx GENTAMICIN TOPICAL approaching US$270 million, when limiting the sales projections to diabetic foot indications only.

About Bupivacaine Surgical Implant

BUPIVACAINE SURGICAL IMPLANT is a biodegradable and fully bioresorbable matrix of purified fibrillar collagen impregnated with the local anesthetic, bupivacaine. It has been specifically developed and formulated using Innocoll's proprietary CollaRx sponge
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. XTL Provides Update on Phase I Clinical Trial of XTL-2125
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
6. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
7. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
8. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
9. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 16 Frost & Sullivan,s ... looks forward to speaking at the 2010 ... place on January 9, 2010 in Las ... emerging market of consumer-based digital health and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, Bujnoch focuses ...
(Date:12/16/2009)... Inc., an inhalation drug delivery company, today announced that ... A financing round, exceeding the targeted total raise amount ... the Series A round will be utilized to continue ... now have the runway and resources to effectively demonstrate ... Rob Neville, CEO of Savara. ,, The company ...
(Date:12/16/2009)... Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), today ... primate study of its novel, once-a-day, oral antibiotic ... tularemia. A 14-day course of Restanza achieved a ... All of the ten animals in the study ... to a human dose of 300 mg) within ...
Breaking Medicine Technology:Frost & Sullivan to Speak at 2010 International Consumer Electronics Digital Health Summit 2Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent 2Advanced Life Sciences' Restanza Shows 100% Survival in Tularemia Pivotal Animal Study 2Advanced Life Sciences' Restanza Shows 100% Survival in Tularemia Pivotal Animal Study 3Advanced Life Sciences' Restanza Shows 100% Survival in Tularemia Pivotal Animal Study 4New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 6657 1New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 6657 2New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 6657 3New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 6657 4New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 6657 5New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 6657 6New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 6657 7Serious Pregnancy Complication Detected With MRI 62389 1Serious Pregnancy Complication Detected With MRI 62389 2Employers Plan to Increase Use of Self Service Decision Making Technology For Open Enrollment Watson Wyatt Survey Finds 62384 1Employers Plan to Increase Use of Self Service Decision Making Technology For Open Enrollment Watson Wyatt Survey Finds 62384 2Employers Plan to Increase Use of Self Service Decision Making Technology For Open Enrollment Watson Wyatt Survey Finds 62384 3
... demonstrating the essential,role of humane animal research ... June 19 The Foundation for,Biomedical Research ... 7th Annual,Michael E. DeBakey Journalism Awards. The ... 2008 Congressional Gold Medal recipient Dr. Michael ...
... 19 Accelerated Community Oncology,Research Network(TM) (ACORN) ... network; Guardian EDC(TM); PACE(TM) PRO System; and,proprietary ... DIA Meeting,June 22-26, in Boston, MA., ... March, 2008 the company announced its Contract ...
Other Medicine Technology:The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards 2ACORN Showcases Oncology CRO, EDC, PRO and Data Warehouse at 44th Annual DIA Meeting 2
(Date:12/16/2009)... , , TUESDAY, Dec. 15 (HealthDay News) -- If that ... on your life that you just can,t wait to have ... you might want to wait at least six months before ... be even better. , The study found that when ... chances of the baby dying, being born prematurely, having birth ...
(Date:12/16/2009)... Inc. ("TSO3") (TSX: TOS) and 3M (MMM) today ... 3M to be the exclusive supplier and distributor ... TSO3, an innovator in low temperature sterilization technology ... use of ozone, will include new cycles to ... channel. This agreement, combined with recent improvements to ...
(Date:12/16/2009)... development of products that help survivors of stroke and other ... publication of an interview with the inventors of their brand ... Therapy and Rehab Medicine, vol. 20, issue 20, page 26, ... ... (PRWEB) December 16, 2009 -- In the publication, ...
(Date:12/16/2009)... another product or thing for your loved ones this holiday season, ... services like housekeeping, errand running, child care, and pet care through ... ... 2009 -- Residents of the Denver and Boulder metro areas have ... friends and loved ones by using Delegate Source,s " Give a ...
(Date:12/15/2009)... a Life Sciences company engaged in the research, development and commercialization of technologies that target ... the Company had proposed at the Annual General Meeting of Shareholders held on December 14, ... Votes ... Non-, Matter ... For Against ...
Breaking Medicine News(10 mins):Health News:For Babies' Sake, Pregnancy Spacing Matters 2Health News:For Babies' Sake, Pregnancy Spacing Matters 3Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 2Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 3Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 4Health News:New Tailwind Device Improves Arm Function in Stroke Survivors with Paralysis 2Health News:Give the Gift of Service This Holiday Season with Delegate Source 2Health News:Give the Gift of Service This Holiday Season with Delegate Source 3Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3
... Against More Diseases than Ever ... ... immunization,recommendations for childhood influenza and adolescent meningococcal,vaccinations are included in the ... for Disease Control and,Prevention (CDC), the American Academy of Pediatrics (AAP), ...
... $450K to Prop ... 93, ... be compelled to buy health insurance under the,Massachusetts mandatory purchase law, according to ... plan pending in,California., As reported in the Boston Globe, Jonathan Gruber, a ...
... 11 International Dairy,Foods Association (IDFA) President and CEO ... Food Safety Authority (EFSA),released its draft report on animal ... United States was a full,year ago with respect to ... animal cloning. Today,s draft scientific report is,simply the first ...
... Comprehensive health care reform is too important, the stakes for, ... ... changes., SACRAMENTO, Calif., Jan. 11 As ... reform,proposal hammered out by Governor Arnold Schwarzenegger and Assembly,Speaker Fabian Nunez, the ...
... officials announced,today that a new generic prescription drug program ... and drugstores., The program offers a 30-day supply ... prescription. The medicines on the list include antibiotics and ... and digestive issues., There are no forms to ...
... how the two sexes evolved , FRIDAY, Jan. 11 (HealthDay News) ... contain clues to gender development in humans. , Duke University researchers ... Nature . , In research with Phycomyces blakesleeanus , ... mating. They named these versions sexM (sex minus) and sexP (sex ...
Other Medicine News:Health News:Health Groups Release 2008 Immunization Schedules 2Health News:MA Proponent of Health Insurance Mandate Says 'Mean' Penalties Needed to Force People to Buy Insurance 2Health News:IDFA: Dairy Processors Urge Further Review of Cloning 2Health News:Insurance Agents Call for State Senate to Improve California's Health Care Reform Compromise 2Health News:Hy-Vee Unveils New Generic Drug Program 2Health News:Fungus Sheds Light on Development of Human Genders 2
... The autoLog™ Autotransfusion System processes blood ... produce washed red blood cells for ... later time. This is achieved with ... An innovative bowl design, coupled with ...
The Wixson Hip Positioner is used for stable positioning of a patient during total hip and revision surgery. It is designed to be placed on top of the operating table....
Stryker Instruments InterPulse System advances the ease and performance of battery powered irrigation for Orthopaedics, Trauma, and Wound Care....
... VersaNail System is a complete system of ... use with TTC fusion surgery. The system ... and integrates clinical research and engineering with ... every patient is different, and because the ...
Medicine Products: